7705-64-8

Upstream product

• 66-39-7 4-(phenylsulfonyl)benzaldehyde 
• 37991-83-6 4-(phenylsulfonyl)benzoyl chloride 
• 18282-51-4 4-iodo-benzyl alcohol 
• 780-69-8 triethoxyphenylsilane 

Downstream Products

• 7705-63-7 1-(bromomethyl)-4-(phenylsulfonyl)benzene 
• 30568-17-3 p-Benzoylsulfonyl-zimtsaeure-methylester 
• 66-39-7 4-(phenylsulfonyl)benzaldehyde 
• 7718-66-3 4-Benzolsulfonyl-benzyljodid 
• 7705-68-2 (4-(phenylsulfonyl)phenyl)methyl methyl ether 
• 7705-67-1 2,3-Bis-<4-benzolsulfonyl-phenyl>-propionsaeure-methylester 
• 7705-65-9 2-(4-Benzenesulfonyl-benzyl)-2,3-bis-(4-benzenesulfonyl-phenyl)-propionitrile 
• 30568-18-4 p-Benzoylsulfonyl-zimtsaeure 

Relevant academic research and scientific papers

A Copper(I)-Catalyzed Sulfonylative Hiyama Cross-Coupling

An air-tolerant Cu-catalyzed sulfonylative Hiyama cross-coupling reaction enabling the formation of diaryl sulfones is described. Starting from aryl silanes, DABSO and aryliodides, the reaction tolerates a large variety of polar functional groups (amines, ketones, esters, aldehydes). Control experiments coupled with DFT calculations shed light on the mechanism, characterized by the formation of a Cu(I)-sulfinate intermediate via fast insertion of a SO2 molecule.

Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof

The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

DIARYLSULFONES AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.

ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.

Quinone Dehydrogenation. Oxidation of Benzylic Alcohols with 2,3-Dichloro-5,6-dicyanobenzoquinone

2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ) reacts with primary and secondary aryl-substituted alcohols under mild conditions in dioxane solution to give the corresponding carbonyl compounds in high yields.In contrast to other oxidants, DDQ can be applied advantageously for the oxidation of hydroxyaryl-substituted alcohols.A mechanism involving participation of the phenolic hydroxyl group in the dehydrogenation reaction is discussed.Oxidations of hydroxyaryl-substituted alcohols by DDQ in methanolsolution resulting in the formation of benzoquinones by loss of the hydroxyaryl side chain are interpreted in terms of phenol oxidation.An example of a pyridine-catalyzed Smiles rearrangement of an o-hydroxy-substituted diphenyl ether is reported.